H 447

Drug Profile

H 447

Alternative Names: EMD-82633; H447; MAb H-447; MDX-447

Latest Information Update: 14 Jun 2004

Price : $50

At a glance

  • Originator IDM S.A.
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Head and neck cancer; Renal cancer; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 14 Jun 2004 No development reported - Phase-I for Renal cancer in USA (unspecified route)
  • 14 Jun 2004 No development reported - Phase-II for Head and neck cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top